HUM at a glance
Humana (HUM, SEC CIK 49071) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on July 29, 2026, an 8-K current report on September 1, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Humana (HUM) reported revenue of $129.7 billion (up 10.1% from FY2024) and net income of $1.2 billion. Diluted EPS was $9.84.
- As of June 30, 2026, 42 institutional investment managers tracked by SignalX reported holding Humana (HUM) shares worth $18.8 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $129.7B
- +10.1% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 42 funds
- $18.8B · +3 vs prior quarter
- Latest 8-K
- Sep 1, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Integrated health insurance services primarily delivering Medicare Advantage and Medicaid plans with complementary healthcare services via CenterWell
- New emphasis on Medicare Advantage individual plans covering 5.2 million members, including approx. 1.0 million in Florida generating $17.8B premiums (20% of individual MA revenue)
- Strategic focus on transitioning providers from fee-for-service to value-based care, enhancing integrated care and member engagement through data analytics
- Medicare Advantage premiums and services revenue $106.3B, comprising 82.6% of segment total; 83% of total revenue derived from federal contracts, CMS-partnered
- Noteworthy: Renewed all Medicare Advantage contracts for 2026, including expanded Florida presence accounting for 14% of consolidated premiums and services revenue
Management Discussion & Analysis
- Revenue $129.7B, up 10.1% YoY; premiums $122.8B (+9.6%), services $5.8B (+31.6%), investment income down 17.9% to $1.0B
- Net income $1.2B, flat YoY (-0.9%); operating margin 2.1% (operating income $2.7B on $129.7B revenue) vs 2.2% in 2024
- Best performing segment: Insurance income from operations $1.7B, up 29.1% on premiums $122.8B; worst: CenterWell flat at $1.3B income despite 12.7% revenue growth
- Benefit ratio 90.2% vs 89.8%; Operating cost ratio increased to 12.0% from 11.8% driven by CenterWell segment; Insurance cost ratio fell slightly to 9.1%
- Value creation charges $449M in 2025; impairments $253M; capital spending reduced (depreciation down 16.8% to $698M)
- Cash flow: No specific CAPEX, dividend, or buyback $ disclosed; operating cash flow seasonally impacted by Medicare design changes
- 2026 outlook: Anticipate Medicare Advantage membership growth (~25% individual, 150k group), PDP growth ~1M; risks from regulatory changes and pricing pressures noted
Risk Factors
- CMS 2025 Medicare Advantage Star Ratings declined, risking lower 2026 quality bonus payments and revenues due to pending lawsuit outcome
- Exposure to geopolitical climate risk from frequent/intense catastrophes including pandemics and hurricanes affecting medical cost trends
- Dependency on third-party IT providers for critical data services risks service disruptions and contract adversities
- Competitive pressure from larger insurers and emerging entrants intensifies premium price containment challenges
- Lawsuit exposure under False Claims Act for Medicare risk-adjustment practices with potential for treble damages and insurance coverage gaps
AI summary of the HUM 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Total revenue $40.9B, up 26.2% YoY from $32.4B, driven by Insurance premiums
- Operating margin 3.3% vs 3.4% YoY, with benefit ratio 91.1% vs 89.7%
- Insurance best-performing segment: revenue $39.0B, up 26.2%; operating income $820M vs $766M
- Stand-alone PDP strongest product: revenue $3.0B, up 74.0% YoY; state-based contracts weakest, up 1.2%
- Cash deployment: $908M MaxHealth acquisition; $56M value-creation charges, with additional charges expected
- Headwinds: BY 2026 Star Ratings, higher new-member benefit ratios, regulatory changes, and anticipated lower favorable claims development
Risk Factors
- No new risk factors; Humana reported no changes from the 2025 Form 10-K
- Regulatory and compliance risks remain those disclosed in the 2025 Form 10-K
- Operational, competitive, and market risks remain unchanged from the 2025 Form 10-K
- Financial risks remain unchanged from the 2025 Form 10-K
AI summary of the HUM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- FY 2026 guidance reaffirmed at least $6.52 GAAP EPS and $9.00 adjusted EPS
- Adjusted EPS excludes $1.47 investment valuation adjustments and $1.27 value creation initiatives
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expanded from 11 to 13 directors effective July 28, 2026
- Frederick J. Crawford and Paul J. Smith elected as independent NYSE-qualified directors
Item 7.01: Regulation FD Disclosure
- Q2 2026 financial results released for quarter ended June 30, 2026
- Detailed earnings release and management remarks available in Exhibits 99.1–99.3
Item EX-99.1: Item EX-99.1
- 2Q26 GAAP EPS $5.73 and adjusted EPS $7.61, up from $4.51 and $6.27 respectively
- Insurance benefit ratio 91.2%, supporting affirmed FY2026 guidance of 92.75% ±25 basis points
AI summaries of HUM 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for HUM
Don't miss the next HUM filing
- Alerts as it files. A push when HUM files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut HUM, by share count.
- Ask anything. An AI agent that reads every HUM filing and answers with sources.
HUM alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| HILZINGER KURT J | A | Sep 30, 2026 | 238 | $384.91 |
| Nundy Shantanu | A | Sep 1, 2026 | 2,549 | - |
| Crawford Frederick John | A | Aug 1, 2026 | 544 | - |
| Smith Paul John | A | Aug 1, 2026 | 544 | - |
| Rechtin James A. | A | May 1, 2026 | 35,633 | - |
| Dintenfass David | A | May 1, 2026 | 11,273 | - |
| Field Robert Stuart | A | May 1, 2026 | 852 | - |
| O'Hara Michelle A. | A | May 1, 2026 | 10,485 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $117.8B | $129.7B |
| Operating Income | - | $2.6B | $2.7B |
| Net Income | $2.5B | $1.2B | $1.2B |
| Op. Margin | - | 2.2% | 2.1% |
| Net Margin | - | 1.0% | 0.9% |
| Balance Sheet | |||
| Total Assets | $47.1B | $46.5B | $48.9B |
| Equity | - | $16.4B | $17.7B |
| ROE | - | 7.4% | 6.7% |
| Per Share | |||
| EPS | $20.00 | $9.98 | $9.84 |
| Cash Flow | |||
| Operating CF | - | $3.0B | $921.0M |
| CapEx | $1.0B | $575.0M | $546.0M |
Source: XBRL data in Humana (HUM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate HUM share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 42 | $18.85B |
| Q1 2026 | 39 | $8.20B |
| Q4 2025 | 40 | $13.59B |
| Q3 2025 | 41 | $15.96B |
| Q2 2025 | 39 | $13.20B |
| Q1 2025 | 35 | $11.26B |
| Q4 2024 | 31 | $8.87B |
| Q3 2024 | 29 | $5.86B |
- T. Rowe Price Group+588.2K (+269%)
- Goldman Sachs Group+394.0K (+21%)
- Citadel Advisors LLC+307.4K (+217%)
- Millennium Management+240.1K (+213%)
- BlackRock+218.7K (+2%)
- Invesco Ltd−907.0K (-38%)
- D.E. Shaw & Co−350.7K (-63%)
- Franklin Resources−246.6K (-90%)
- Bank of America Corp−103.3K (-13%)
- Ameriprise Financial−100.2K (-26%)
- Two Sigma Investments−58.7K
- Marex Group plc−4.8K
- Blackstone Group−1.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 296 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
HUM filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 8-K | Sep 1, 2026 | - | Analysis | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 10-Q | Jul 29, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jun 1, 2026 | - | Analysis | |
| 8-K | May 19, 2026 | - | Analysis | |
| 4 | May 5, 2026 | - | - | - |
| 4 | May 5, 2026 | - | - | - |
| 4 | May 5, 2026 | - | - | - |
| 4 | May 5, 2026 | - | - | - |
| 4 | May 5, 2026 | - | - | - |
| 4 | May 5, 2026 | - | - | - |
| 4 | May 5, 2026 | - | - | - |
| 4 | May 5, 2026 | - | - | - |
| 4 | May 5, 2026 | - | - | - |
| SC 13G | Apr 30, 2026 | - | - | |
| 10-Q | Apr 29, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 29, 2026 | - | Analysis | - |
| 8-K | Apr 20, 2026 | - | Analysis | - |
| 8-K | Apr 10, 2026 | - | Analysis | - |
| 4 | Apr 3, 2026 | - | - | - |
Related Health Care companies
- ALHC · Alignment Healthcare, Inc.Hospital & Medical Service Plans
- CNC · Centene CorporationHospital & Medical Service Plans
- CI · CignaHospital & Medical Service Plans
- CLOV · CLOVER HEALTH INVESTMENTS, CORP. /DEHospital & Medical Service Plans
- ELV · Elevance HealthHospital & Medical Service Plans
- MOH · Molina HealthcareHospital & Medical Service Plans
- OSCR · Oscar Health, Inc.Hospital & Medical Service Plans
- TRUP · TRUPANION, INC.Hospital & Medical Service Plans
HUM SEC filings: frequently asked questions
Which institutions hold HUM stock?
As of June 30, 2026, the largest Humana (HUM) holders among the 13F filers tracked by SignalX were BlackRock ($4.1 billion), Vanguard Capital Management LLC ($3.1 billion), Vanguard Portfolio Management LLC ($2.3 billion), State Street Corp ($2.2 billion), JPMorgan Chase & Co ($1.3 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was HUM's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Humana (HUM) reported revenue of $129.7 billion (up 10.1% from FY2024) and net income of $1.2 billion. Diluted EPS was $9.84. The figures come from the XBRL data in the 10-K.
What are the main risks in HUM's latest 10-K?
In the 10-K filed February 19, 2026, Humana (HUM) flagged: CMS 2025 Medicare Advantage Star Ratings declined, risking lower 2026 quality bonus payments and revenues due to pending lawsuit outcome. Exposure to geopolitical climate risk from frequent/intense catastrophes including pandemics and hurricanes affecting medical cost trends. (AI summary of the Risk Factors section.)
What did HUM report in its latest 8-K?
Humana (HUM) filed an 8-K on September 1, 2026 reporting Item 7.01 (Regulation FD Disclosure). FY 2026 guidance reaffirmed at least $6.52 GAAP EPS and $9.00 adjusted EPS.
What are the latest HUM SEC filings?
Humana (HUM) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on July 29, 2026, an 8-K current report on September 1, 2026 and a Form 4 insider filing on October 2, 2026.
What is HUM's SEC CIK number?
Humana (HUM)'s SEC Central Index Key (CIK) is 49071. EDGAR lists every HUM filing under that number.
Ask anything about HUM
The research agent reads HUM's filings, financials, insider trades and 13F holders, then answers with sources.